

# GZD824

**Catalog No: tcsc1444**



## Available Sizes

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

1257628-77-5

**Formula:**

$C_{29}H_{27}F_3N_6O$

**Pathway:**

Protein Tyrosine Kinase/RTK

**Target:**

Bcr-Abl

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

532.56

## Product Description

GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.


IC50 Value: 0.34/0.68 nM(Bcr-Abl wt/T315I) [1]

Target: Bcr-Abl

in vitro: GZD824 potently suppressed proliferation of Bcr-Abl-positive K562 and Ku812 human CML cells with IC(50) values of 0.2 and 0.13 nM, respectively. It also displayed good oral bioavailability (48.7%), a reasonable half-life (10.6 h), and promising in vivo antitumor efficacy.

in vivo: GZD824 induced tumor regression in mouse xenograft tumor models driven by Bcr-Abl(WT) or the mutants and significantly improved the survival of mice bearing an allograft leukemia model with Ba/F3 cells harboring Bcr-Abl(T315I) [1].

Clinical trial: GZD824 is on the way of unknown clinical status.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!